OncoMatch/Clinical Trials/NCT06904196
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Is NCT06904196 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Lenvatinib plus SIRT and Lenvatinib for hepatocellular carcinoma non-resectable.
Treatment: Lenvatinib plus SIRT · Lenvatinib — This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: hepatic arterial infusion chemotherapy
Patients who received prior hepatic arterial infusion chemotherapy (HAIC)
Cannot have received: radiotherapy
Patients who received prior radiotherapy
Cannot have received: systemic therapy
Patients who received prior systemic therapy, for HCC
Lab requirements
Blood counts
platelet count ≥50×10^9/L, leukocyte >3.0×10^9/L, Neutrophil count ≥1.5×10^9/L, haemoglobin ≥85 g/L
Kidney function
creatinine≤1.5×ULN
Liver function
ALT and AST≤5×ULN, albumin ≥28 g/L, total bilirubin ≤3× ULN, prolongation of prothrombin time ≤4 seconds
Adequate organ and hematologic function with platelet count ≥50×10^9/L, leukocyte >3.0×10^9/L, Neutrophil count ≥1.5×10^9/L, haemoglobin ≥85 g/L, ALT and AST≤5×ULN, albumin ≥28 g/L, total bilirubin ≤3× ULN, creatinine≤1.5×ULN, and prolongation of prothrombin time ≤4 seconds
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06904196 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages